Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28529745 | 0.85 | GAA (0.53) | GAAALDH1A1ASAH1MEN1KMT2A | |
| SCHEMBL26353713 | 0.78 | GAA (0.69) | GAAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL19485799 | 0.78 | GAA (0.63) | GAAALDH1A1KDM4EMAPTRECQL | |
| SCHEMBL16729201 | 0.77 | GAA (0.83) | GAAALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL24181345 | 0.77 | GAA (0.83) | GAAALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL18716984 | 0.77 | GAA (0.49) | GAAALDH1A1RECQL | |
| SCHEMBL21792191 | 0.77 | ALDH1A1 (0.47) | GAAALDH1A1TSHR | |
| SCHEMBL29475669 | 0.77 | GAA (0.55) | GAAALDH1A1KMT2ARECQL | |
| SCHEMBL28656285 | 0.77 | GAA (0.55) | GAAALDH1A1KMT2ARECQL | |
| SCHEMBL26347009 | 0.77 | GAA (0.55) | GAAALDH1A1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317213-A1 | Anti-CD3 Antibody Folate Bioconjugates and Their Uses | AMBRX, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317213-A1 | Anti-CD3 Antibody Folate Bioconjugates and Their Uses | FOLR2, FOLR1, CD2 | GAA 608/4885ALDH1A1 2499/4885ASAH1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.